Showing 431-440 of 5950 results for "".
Evaluating the Interleukin Antibodies and Their Future in Psoriasis Therapy
https://practicaldermatology.com/topics/psoriasis/PD0809_13-php/22791/New investigational therapies blocking IL-12/23 may offer new possibilities in the treatment of psoriatic disease.FDA Grants Interchangeability to HADLIMA
https://practicaldermatology.com/series/dermwire-tv/fda-grants-interchangeability-to-hadlima/35962/In this week's DermwireTV, the FDA grants full interchangeability to HADLIMA; new research shows the impact of UV exposure on global skin cancer cases; and coverage from Music City SCALE addresses barriers to patient access to new therapies.Leadership Without Authority:Influencers of Culture in Your Practice
https://practicaldermatology.com/issues/may-june-2025/leadership-without-authority-influencers-of-culture-in-your-practice/35924/Influencers in popular culture demonstrate how individuals without formal authority can shape trends, ideas, and behavior.Mechanisms for Food Allergy Initiation by Skin Pre-disposed to Atopic Dermatitis
https://practicaldermatology.com/issues/may-june-2025/mechanisms-for-food-allergy-initiation-by-skin-pre-disposed-to-atopic-dermatitis/35922/In this research report, we highlight a 2024 study by Gao et al. investigating the mechanisms underlying food allergy initiation in neonates susceptible to atopic dermatitis (AD).Nail Disease and JAK Inhibitor Safety
https://practicaldermatology.com/programs/practical-dermatology/nail-disease-and-jak-inhibitor-safety/35897/Brad Glick, DO, talks about the basics of nail anatomy, physiology, disease presentation, and treatments, as well as the safety of JAK inhibitors, at Music City SCALE 2025.AAD Leaders Discuss New Goals and Initiatives
https://practicaldermatology.com/series/dermwire-tv/aad-leaders-discuss-new-goals-and-initiatives/33154/In this week's DermwireTV, leaders of the American Academy of Dermatology (AAD) discuss the key issues facing the specialty; a new study examines nicotinamide exposure and the risk of major adverse cardiovascular events; and in our C-Suite Chats segment, we hear from an Executive Director at TakeTalking to Patients About Starting a JAK Inhibitor in Atopic Dermatitis
https://practicaldermatology.com/series/pa-perspectives/talking-patients-about-starting-jak-inhibitor-atopic-dermatitis/26919/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, discusses the importance of offering patients quick access to medication, and tips on how to best discuss safety.Get Ready for JAK Inhibitors
https://practicaldermatology.com/topics/psoriasis/get-ready-for-jak-inhibitors/19928/JAK inhibitors are going to change the way we think about refractory disease, says Brett King, MD. He addresses the significant increase in study of these agents and the many potential uses for refractory diseases like alopecia, atopic dermatitis, vitiligo, psoriasis, and more.Reduce Your Life Insurance Costs
https://practicaldermatology.com/topics/practice-management/reduce-your-life-insurance-costs/20630/You “refi” your mortgage when rates go down. Here are seven reasons to do the same for your life insurance.Interoperability Update
https://practicaldermatology.com/topics/practice-management/interoperability-update/20674/Are PHRs the key to interoperability?